Mundipharma closes asset purchase agreement with Vital Food Processors

Published: 7-Sep-2018

The company has secured the global rights to commercialise a digestive health supplement extract from kiwifruit

Mundipharma has closed an asset purchase agreement with Vital Food Processors, an agricultural science company founded in New Zealand, for the global rights beyond New Zealand to commercialise Zyactinase – a clinically-proven gastrointestinal consumer health product.

Zyactinase is a freeze-dried extract of Kiwifruit (Actinidia deliciosa) that has been developed as a constipation relief product as well as for long-term gut health. It contains a protease complex, fiber, pectin and fructo-oligosaccharides that stimulates increased bowel movements.

Under the agreement, Mundipharma will initially focus on the commercialising Zyactinase to establish a foothold in the US and Canada markets, while continuing to supply existing partners. It will then look to expand its marketing and distribution footprint globally.

This agreement will also enable the extension of the company’s Senokot product range in the US, which is also an all natural, clinically proven digestive health supplement for the treatment of constipation.

“We are delighted to have realised this opportunity to acquire a unique, clinically-proven differentiated formulation for commercialisation on a global basis across our network,” said Mundipharma CEO, Raman Singh.

“As well as providing a consumer pathway for a great product, this strategic acquisition also enables us to extend our depth and competitiveness in the digestive health category,” he added.

Dr Oliver Summerfield, Vital Foods CEO and Principal at majority investor Inventages Venture Capital, commented: “We believe this deal recognises the value created by Vital Foods’ technology platform and that Mudipharma are a strong partner for the global commercialisation of the clinically-proven digestive health product developed by Vital Foods’ team.”

You may also like